CBL0137 for children with advanced solid or brain tumors
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 12 months to 21 years at enrollment
- A confirmed cancer diagnosis (biopsy/pathology) or, for certain brain tumors, specific tumor-marker/imaging situations
- Cancer that has returned or is not responding, and there’s no proven curative option
- Cancer that can be measured (or, for one part of the study, may be “evaluable”) per study checks
- Recovered from prior cancer treatment and blood counts/organ tests meet study limits
- Can take CBL0137 through a central venous (central) line
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a new immune cell therapy for people with a specific type of brain tumor (diffuse midline glioma or diffuse intrinsic pontine glioma) that has returned or not responded to standard treatment. The treatment uses specially engineered immune cells to target a protein called H3K27M, which is found on these tumors. This study aims to see if this therapy is safe and effective.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
This trial tests a new drug called CBX-663 in people with certain blood cancers, solid tumors, or glioblastoma that have returned or not responded to standard treatment. It aims to see if the drug is safe and helps shrink or control the cancer.
Hear when a new Diffuse Midline Glioma, H3 K27-Altered trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.